An improved long-term sales target today revitalised GSK shares after their dismal 2024. The confidence in GSK’s drugs pipeline came alongside results pointing to top line growth between 3% and 5% in ...

OPEN The FTSE 100 was expected to open 115.1 points lower ahead of the opening bell on Monday, after wrapping up the previous session 1.24% softer at 10,284.75.

A setback for GSK after one of its late-stage pipeline assets failed to win the support of a US panel today triggered a 6% reverse for its FTSE 100-listed shares. GSK recently identified multiple ...

GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified portfolio ...

GlaxoSmithKline is now known simply as GSK. GSK stock trades for 13 times earnings and barely 11 times free cash flow. The pharmaceutical giant pays a 3.3% dividend yield and is growing earnings in ...